拉米夫定联合白细胞介素-2治疗慢性乙型肝炎的临床疗效分析

Clinical curative effect of lamivudine combined with interleukins-2 on treatment of chronic hepatitis B

目的探讨拉米夫定联合白细胞介素-2治疗慢性乙型肝炎的临床疗效,为临床治疗提供参考。方法将68例慢性乙型肝炎患者随机分为治疗组与对照组各34例,两组均给予拉米夫定口服,治疗组加用白细胞介素-2皮下注射,疗程48周。结果在治疗12、24周时,治疗组HBV-DNA转阴率分别为11.43%、28.57%,HBeAg血清学转换率分别为0、8.57%,对照组HBV-DNA转阴率分别为8.57%、22.86%,HBeAg血清学转换率分别为0、5.71%,两组之间比较差异无统计学意义,在治疗48周时,治疗组HBV-DNA转阴率与HBeAg血清学转换率分别为58.82%、41.18%,对照组为33.33%、15.15%,两组比较差异有统计学意义(P<0.05);用药期间两组均未发生严重不良反应。结论拉米夫定联合白细胞介素-2治疗慢性乙型肝炎疗效优于单药治疗,安全性高。

OBJECTIVE To investigate the clinical curative effect of lamivudine combined with interleukins-2 on the treatment of chronic hepatitis B so as to provide basis for the clinical treatment. METHODS A total of 68 cases of chronic hepatitis B patients were randomly divided into the treatment group and the control group with 34 cases in each, both groups were given the oral lamivudine, the treatment group was added with the subcutaneous injection of interleukins-2 for a 48-week treatment course. RESULTS In the treatment group,the negative rates of HBV- DNA on the 12th and 24th week after the treatment were 11.43% and 28.57%, respectively, and the conversion rates of HBeAg serology were 0% and 8.57% ,respectively,while in the control group the negative rates of HBV- DNA were 8. 57% and 22. 86%, respectively, and the conversion rates of the HBeAg serology were 0% and 5.71%, respectively, the difference between the two groups was not statistically significant （P〈0.05）. On the 48th week after the treatment,the negative rate of HBV-DNA was 58.82% in the treatment group and 33.33% in the control group,while the conversion rate of HBeAg serology was 41.18% in the treatment group and 15.15% in the control group, the difference between the two groups was statistically significant （P〈0.05） ; there were no cases of severe adverse reactions that occurred during the medication. CONCLUSION Lamivudine combined with interleukins-2 is superior to the single drug in the curative effect on the treatment of chronic hepatitis B.